These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 15191443

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of first-trimester contingent screening strategies for Down syndrome.
    Sahota DS, Leung TY, Chan LW, Law LW, Fung TY, Chen M, Lau TK.
    Ultrasound Obstet Gynecol; 2010 Mar; 35(3):286-91. PubMed ID: 20052660
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K, Bindra R, Cacho AM, Nicolaides KH.
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [Abstract] [Full Text] [Related]

  • 8. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
    Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM.
    Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F, Damiani G, Hallahan TW, Krantz DA, Macri JN.
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [Abstract] [Full Text] [Related]

  • 13. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [Abstract] [Full Text] [Related]

  • 14. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K, Nicolaides KH.
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.